![](/img/cover-not-exists.png)
The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program
Pivot, X., Poole, C., Martín, M., Gligorov, J., Barrios, C.H., Vrdoljak, E., Zambetti, M., Woodward, N., Ten Tije, A.J., Lindegger, N., Crespel, G., Truman, M., Steger, G.G.Volume:
92
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(18)30542-2
Date:
April, 2018
File:
PDF, 63 KB
english, 2018